{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:39:43Z","timestamp":1779910783942,"version":"3.53.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"European Cardiovascular Research Institute"},{"name":"Biosensors International Ltd"},{"name":"Astra Zeneca"},{"name":"Medicines Company, Parsippany"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The efficacy and safety of continued bivalirudin infusion after percutaneous coronary intervention (PCI) remains uncertain. We sought to investigate the association between post-PCI bivalirudin infusion and the risk of net adverse clinical events (NACE) at 30\u2009days.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>In the GLOBAL LEADERS study, all patients who received bivalirudin during PCI were categorized according to the use of bivalirudin infusion after the procedure. The primary endpoint of the present analysis was NACE [a composite of all-cause death, any stroke, any myocardial infarction, all revascularization, and bleeding assessed according to the Bleeding Academic Research Consortium (BARC) criteria Type 3 or 5] at 30\u2009days. The key safety endpoint was BARC Type 3 or 5 bleeding and definite stent thrombosis. Of 15\u00a0968 patients, 13\u00a0870 underwent PCI with the use of bivalirudin. In total, 7148 patients received continued bivalirudin infusion after procedure, while 6722 patients received standard care. After propensity score covariate adjustment, the risk of NACE did not significantly differ between two treatments after PCI [continued bivalirudin infusion vs. no bivalirudin infusion: 3.2% vs. 3.1%, adjusted hazard ratio (aHR) 1.35, 95% confidence interval (CI) 0.99\u20131.84, P\u2009=\u20090.06] nor the BARC Type 3 or 5 bleeding (0.7% vs. 0.7%, aHR 0.89, 95% CI 0.44\u20131.79; P\u2009=\u20090.743) and definite stent thrombosis (0.5% vs. 0.3%, aHR 1.71, 95% CI 0.77\u20133.81, P\u2009=\u20090.189). However, continued bivalirudin infusion was associated with an increased risk of NACE and definite stent thrombosis in ST-elevation myocardial infarction (STEMI) patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In an all-comers population undergoing PCI, there was no significant difference in the risk of NACE at 30\u2009days between continued bivalirudin infusion vs. no bivalirudin infusion after procedure but continued bivalirudin infusion was associated with a higher risk of NACE in STEMI patients when compared with no infusion.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvz051","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T15:11:12Z","timestamp":1575558672000},"page":"22-30","source":"Crossref","is-referenced-by-count":10,"title":["Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study"],"prefix":"10.1093","volume":"6","author":[{"given":"Chun Chin","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Doctor Molewaterplein 40, GD Rotterdam, Netherlands"},{"name":"Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Beitou 11217, Taipei, Taiwan"},{"name":"Institute of Clinical Medicine, National Yang Ming University, Beitou 11221, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ply","family":"Chichareon","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands"},{"name":"Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai 90110, Songkhla, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0047-7859","authenticated-orcid":false,"given":"Rodrigo","family":"Modolo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5748-7700","authenticated-orcid":false,"given":"Kuniaki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5724-9243","authenticated-orcid":false,"given":"Norihiro","family":"Kogame","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8289-1393","authenticated-orcid":false,"given":"Mariusz","family":"Tomaniak","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Doctor Molewaterplein 40, GD Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Gao","sequence":"additional","affiliation":[{"name":"Cardiology Department, Radboudumc, Comeniuslaan 4 6525 HP, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kees-Jan","family":"Royaards","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Maasstad Hospital, Maasstadweg 21, 3079 DZ, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Cequier","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bellvitge University Hospital, IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Oldroyd","sequence":"additional","affiliation":[{"name":"West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Clydebank, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"Cardiology Department, AP-HP, Hospital, Bichat, 75018 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hamm","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kerckhoff Heart Center, 61231Bad Nauheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"J\u00fcni","sequence":"additional","affiliation":[{"name":"Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, M4P 1A6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2653-6762","authenticated-orcid":false,"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Onuma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Doctor Molewaterplein 40, GD Rotterdam, Netherlands"},{"name":"Cardialysis B.V., 3012 KM Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rod H","family":"Stables","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jan van Geuns","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Doctor Molewaterplein 40, GD Rotterdam, Netherlands"},{"name":"Cardiology Department, Radboudumc, Comeniuslaan 4 6525 HP, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9636-1104","authenticated-orcid":false,"given":"Patrick W","family":"Serruys","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,9]]},"reference":[{"key":"2020010703580471900_pvz051-B1","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"2020010703580471900_pvz051-B2","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"2020010703580471900_pvz051-B3","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial","volume":"384","author":"Shahzad","year":"2014","journal-title":"Lancet"},{"key":"2020010703580471900_pvz051-B4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jcin.2008.10.004","article-title":"Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial","volume":"1","author":"Lincoff","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"2020010703580471900_pvz051-B5","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jcin.2014.11.002","article-title":"Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography)","volume":"8","author":"Clemmensen","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"2020010703580471900_pvz051-B6","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","article-title":"Bivalirudin versus heparin monotherapy in myocardial infarction","volume":"377","author":"Erlinge","year":"2017","journal-title":"N Engl J Med"},{"key":"2020010703580471900_pvz051-B7","first-page":"2541","article-title":"Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)","volume":"35","author":"Authors\/Task Force","year":"2014","journal-title":"Eur Heart J"},{"key":"2020010703580471900_pvz051-B8","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.4244\/EIJY19M01_01","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"14","author":"Neumann","year":"2019","journal-title":"EuroIntervention"},{"key":"2020010703580471900_pvz051-B9","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMe1709247","article-title":"Procedural anticoagulation in myocardial infarction","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2020010703580471900_pvz051-B10","doi-asserted-by":"crossref","first-page":"e003515","DOI":"10.1161\/JAHA.116.003515","article-title":"Continued high-dose bivalirudin infusion reduces major bleeding without increasing stent thrombosis in patients undergoing primary percutaneous coronary intervention: novel insights from an updated meta-analysis","volume":"5","author":"Fahrni","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2020010703580471900_pvz051-B11","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4244\/EIJY15M11_07","article-title":"Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial","volume":"12","author":"Vranckx","year":"2016","journal-title":"EuroIntervention"},{"key":"2020010703580471900_pvz051-B12","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"2020010703580471900_pvz051-B13","doi-asserted-by":"crossref","DOI":"10.4244\/EIJ-D-19-00202","article-title":"Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomized GLOBAL LEADERS trial","author":"Serruys","year":"2019","journal-title":"EuroIntervention"},{"key":"2020010703580471900_pvz051-B14","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"2020010703580471900_pvz051-B15","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"2020010703580471900_pvz051-B16","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1093\/eurheartj\/ehy223","article-title":"Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document","volume":"39","author":"Garcia-Garcia","year":"2018","journal-title":"Eur Heart J"},{"key":"2020010703580471900_pvz051-B17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"2020010703580471900_pvz051-B18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"2020010703580471900_pvz051-B19","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1507854","article-title":"Bivalirudin or unfractionated heparin in acute coronary syndromes","volume":"373","author":"Valgimigli","year":"2015","journal-title":"N Engl J Med"},{"key":"2020010703580471900_pvz051-B20","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacc.2018.12.023","article-title":"Post-procedural bivalirudin infusion at full or low regimen in patients with acute coronary syndrome","volume":"73","author":"Gargiulo","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2020010703580471900_pvz051-B21","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jama.2015.2323","article-title":"Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial","volume":"313","author":"Han","year":"2015","journal-title":"JAMA"},{"key":"2020010703580471900_pvz051-B22","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI","volume":"369","author":"Steg","year":"2013","journal-title":"N Engl J Med"},{"key":"2020010703580471900_pvz051-B23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ccd.27828","article-title":"Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention","volume":"93","author":"Shah","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"2020010703580471900_pvz051-B24","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.4244\/EIJ-D-17-00307","article-title":"Bivalirudin infusion to reduce ventricular infarction: the open-label, randomised Bivalirudin Infusion for Ventricular InfArction Limitation (BIVAL) study","volume":"13","author":"van Geuns","year":"2017","journal-title":"EuroIntervention"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvz051\/31549009\/pvz051.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/6\/1\/22\/31717473\/pvz051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/6\/1\/22\/31717473\/pvz051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T03:58:42Z","timestamp":1578369522000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/6\/1\/22\/5670529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,9]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12,9]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvz051","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2019,12,9]]}}}